At HLTH, Bessemer investors Sofia Guerra and Steve Kraus detailed four predictions about where they think the digital health world is headed in 2024. One of these was that "services-as-software" will emerge as a new category of healthcare AI. Another was that some healthcare technology vendors will have to rethink their distribution models and rely on indirect monetization strategies.
At HLTH, General Catalyst Principal Candace Richardson discussed some of the questions she frequently asks startups during investment meetings. Some of these include "Do you stratify your outcomes data by different populations to ensure your model works well for everyone?" and "Is serving Medicaid populations on your roadmap?"
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Healthcare IT companies raised $1 billion in venture capital in Q2 — down slightly from the $1.3 billion raised in Q1 but up significantly from the $451.3 million raised in Q4 2022. Unsurprisingly, a lot of these investments were made in companies offering generative AI products. Another key trend was increasing cash flow to remote patient monitoring startups, likely caused by expanded reimbursement for these services.
About 31 telemedicine programs will receive $8.6 million in federal grant money for healthcare programs as part of a wider move by the government in support of telemedicine as a way to help patients see primary care physicians and specialists faster, especially in rural communities. The rural telemedicine grants are provided by the U.S. Department […]
Vida, a mobile health startup, has launched a 24/7 service that uses live interactions with physicians through text and video to steer people to make better health and fitness decisions. The move comes after eight months of Beta testing its service, which is geared to helping people with chronic conditions, such as diabetes or hypertension, […]
A little over a year after it opened a Boston innovation center, Johnson & Johnson (NYSE: JNJ) unveiled a series of research and development collaborations and investments in early-stage companies that reads like a smorgasboard of cutting-edge biotechnology and medical devices. It includes collaborations with six Massachusetts companies and gives a sense of the big […]
Proteus Digital Health, with an FDA-approved technology embedded in medication that can confirm whether people have taken their meds, has raised $120 million from new investors. The Internet of Things company offers a compelling approach to whittling down costs related to poor compliance estimated at nearly $300 billion. Proteus Digital Health will use the fresh […]
A medical device developer got a big boost in its efforts to develop a surgical sealant for brain surgery. Endomedix received a $1.49 million Phase 2 Small Business Innovation Research grant to help control bleeding for surgical procedures, according to a company statement. It received the grant from the National Institute of Neurological Disorders and […]
The cost associated with diabetes, $245 billion at last count, has led several companies to develop digital health tools to help either medical professionals or patients do a better job of managing their health. Boosting adherence through different approaches to patient engagement or health literacy is a constant theme. The idea is to reduce healthcare […]
StartUp Health Insights – Q1 2014 Update from StartUp Health Last year investments in big data dominated health IT deals as 112 deals attracted $712 million in investments, according to a new report by StartUp Health assessing digital health investment trends in 2013 and the start of this year. But in a trend that’s likely […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
